CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
Crispr Therapeutics call volume above normal and directionally bullish
Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,734 calls trading, 1.3x expected, and implied vol increasing almost 4 points ...
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
CRISPR Therapeutics AG (CRSP): The Biotech Stock with Biggest Upside Potential
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...
FierceBiotech1d
RFK Jr. pledges to divest interests in CRISPR Tx, Dragonfly if HHS role confirmed
Robert F. Kennedy Jr. will be pulling his investments from two biotechs if he is confirmed to lead the U.S. Department of ...
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
My Top 5 Stocks to Buy in Early 2025
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...
Nasdaq6d
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...